InsidersTradesSigma
Beta Bionics, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Beta Bionics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Market capitalisation: €755.3m. The latest transaction was reported on 30 June 2026 (Levée d'options). Among the most active insiders: Feider Stephen. Every trade is openly available.
91
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€2m
40 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Beta Bionics, Inc. Buy (bullish), based on 11 analysts. Average price target: US$19.18.
54Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 23,599 of 26,671 companies
23.5
score / 100
Value18
Quality30
FCF yld-7.4%
Earn yld-9.7%
EV/EBITDA·
ROE-23%
Gross mgn55%
Net mgn-73%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 June 2026
Declarations91 total
4,982 sharesCommon StockSEC:0002048588-26-000009:0
5,104 sharesCommon StockSEC:0002048588-26-000009:1
4,896 sharesCommon StockSEC:0002048588-26-000009:2
4,896 sharesCommon StockSEC:0002048588-26-000009:3
4,896 shares@ US$17.03040.012% mcap48.8% of flowCommonSEC144:0001628280-26-045940
5,104 shares@ US$17.04680.012% mcap51.2% of flowCommonSEC144:0001628280-26-045803
1,406 sharesCommon StockSEC:0002048467-26-000005:0
1,258 sharesCommon StockSEC:0002048497-26-000009:0
1,258 shares@ US$14.96570.0026% mcap100.0% of flowCommonSEC144:0001628280-26-045235
1,406 shares@ US$13.670.0027% mcap100.0% of flowCommonSEC144:0001950047-26-006469
2,811 shares@ US$14.000.0048% mcap66.5% of flowCommon StockSEC:0002048467-26-000004:0
275 shares@ US$12.310.0004% mcap4.8% of flowCommon StockSEC:0002048497-26-000008:0
275 shares@ US$12.31CommonSEC144:0001628280-26-040713
5,329 shares@ US$12.79Common StockSEC144:0002048497-26-000006
4,378 shares@ US$12.79Common StockSEC144:0002048500-26-000008
6,676 shares@ US$12.79Common StockSEC144:0002048588-26-000007
16,872 shares@ US$12.79Common StockSEC144:0002048593-26-000005
4,222 shares@ US$12.79Common StockSEC144:0002051384-26-000005
5,329 shares@ US$12.6071100.0% of flowCommon StockSEC:0002048497-26-000007:0
4,378 shares@ US$12.6071100.0% of flowCommon StockSEC:0002048500-26-000009:0
6,676 shares@ US$12.607114.8% of flowCommon StockSEC:0002048588-26-000008:0
16,872 shares@ US$12.6071100.0% of flowCommon StockSEC:0002048593-26-000006:0
4,222 shares@ US$12.6071100.0% of flowCommon StockSEC:0002051384-26-000006:0
16,965 shares0Common StockSEC:0001239312-26-000003:0
16,965 shares0Common StockSEC:0001756438-26-000003:0
25 of 91 declarations
About Beta Bionics, Inc.
Beta Bionics, Inc. is a company focused on developing medical technologies for diabetes treatment. It aims to create innovative devices to enhance disease management.